Is Novavax a Buy?
In the race to develop COVID-19 vaccines, Novavax (NASDAQ: NVAX) seems to have gotten the most important part right. The latest clinical trial data for the NVX-CoV2373 vaccine showed 90% overall efficacy against early variants after demonstrating 96% efficacy against the original strain.
These preliminary results appear comparable to Moderna and Pfizer's vaccines, but more data is required to understand how well NVX-CoV2373 performs against the delta variant. Novavax is expected to file for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in September, after which more data should be forthcoming. What comes next will determine whether Novavax enjoys a massive global business or watches this opportunity pass it by as vaccine competitors take the market.
Image source: Getty Images.
Source Fool.com
